Glycosal producer Provalis sees turnaround - on cue
This article was originally published in Clinica
Executive Summary
As predicted in reports this time last year, Provalis' diagnostics division had a markedly improved 12 months to June 30 2003, the company's medical diagnostics division reporting record sales of £3.1m ($4.9m). This was against a disappointing £900,000 in 2001-2002.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.